Brain health monitoring with eye movements smartphones.
The BLUE DOT game measures eye movements.
We generate gaze point metrics that measure brain health.
CONCUSSION
Objectively measure impairments
We offer advanced eye-tracking metrics to objectively measure impairments due to concussion.
Track progression
Continuous monitoring of eye movement impairments provide a sensitive measure for progression and treatment efficacy of mTBI and concussion.
Early Detection of Neurodegenerative disease
Work is in progress on proof-of-concept validation of eye movement metrics for Alzheimers and related dementia, Parkinson's and Multiple Sclerosis.
Insights on brain health by playing a game
Our BLUE DOT game, based on the WebGrid game from Neuralink provides for continuous monitoring and analysis of eye movements.
It has been established that pathological changes in the brain occur many years prior to disease onset. Early symptoms include subtle cognitive and memory issues, followed by the phase of Mild Cognitive Impairment (MCI) prior to the established disease. Although the prodromal phase may remain undetected, this is the stage where intervention may be most successful. Eye-tracking can detect the subtle cognitive changes that occur prior to a diagnosis.
Early identification of those at high risk for neurodegenerative disease is an unmet need.
Team
Dr. Luc Ghislain, CEO
Luc is dedicated to innovation, teamwork, and strategic collaboration. Has an extensive background assembling dynamic teams and launching groundbreaking products. At Labcyte, a cutting-edge biotools startup, he worked across a full spectrum of technologies. He cultivated early adopter technology partnerships with pharma such as AstraZeneca, GSK, and Pfizer. He led a high-throughput analysis instrument from concept to launch -- this was both a real challenge and a highlight. Labcyte was acquired by Beckman Coulter Life Sciences in 2019.
Advisory Board
Viveka (Ågren) Rydell-Anderson JD, MSc
Viveka is a seasoned and passionate lawyer and healthcare leader with over 20 years of experience in law, healthcare, technology, and business. As the CEO of Pacific Vision Foundation, she leads a dynamic and diverse team of professionals who are committed to improving the quality of life of underserved communities in the Bay Area and beyond.
Her mission is to drive the future of healthcare delivery, offering individualized, patient-centered, and fully-integrated care. She am skilled in innovation management, change management, international business development, and startups, and a
recognized business leader and healthcare leader.
Sammy Datwani, Ph.D.
Sammy is an innovative and strategic results-oriented leader with a demonstrated history developing emergent technologies and commercializing disruptive revolutionary life science and medical device products. 20+ years of executive and leadership experience developing solutions that allow customers to meet their research and commercial objectives. He is a dynamic team builder and leader for teams spanning multiple functions and locations including R&D, Innovation, Business Development, Corporate Strategy, Product Development, Intellectual Property Development, Program Management, Angel Investing, Fundraising, Startups, Expert Witness and Advocacy.
Karim Refaey M.D., M.S.E.
I’m a physician-scientist turned venture capitalist at DigitalDx Ventures, where we invest in early-stage diagnostics and AI-enabled tools.
Before VC, I completed my MD from Egypt, an MSE in Biomedical Engineering from Johns Hopkins, and Neurosurgery from Johns Hopkins and Mayo Clinic. My research focused on NeuroTech, Epilepsy, and Brain-Computer Interfaces.
I held roles in Big Pharm like Siemens Healthineers, Johnson & Johnson, and Abbott which has deepened my understanding of clinical development, regulatory pathways, and commercialization strategies in healthcare.
Gordon Murtaugh
Gordon Murtaugh is a management consultant specializing in helping build early-stage companies. He has operated his own consulting practice for over 20 years, including periods in which he held operating management roles at clients. He has worked with over 50 clients in biotech, pharmaceutical, healthcare, software, finance, manufacturing, renewable energy and professional services. Gordon previously led business development for Philips Healthcare’s consulting business from 2015 to 2018, coming to Philips by way of its acquisition of Blue Jay Consulting, where he had been Vice President. Gordon’s business development team at Philips was responsible for selling management consulting services to hospitals in North America. He also prepared the first business plan for Wellcentive, a population health software company, which was also acquired by Philips Healthcare in 2016. Gordon holds an AB degree in Biochemistry from Brown University and MBA degree from Harvard Business School.